PharmaEssentia Plans New U.S. Manufacturing Facility In Puerto Rico
(Photo: PharmaEssentia)
Taiwan-based PharmaEssentia Corporation and its Massachusetts-based U.S. subsidiary PharmaEssentia USA Corporation will invest approximately $46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico. PharmaEssentia is a global biopharmaceutical company that develops novel biologics for hematology and oncology.
Ko-Chung Lin, Ph.D.
Founder, CEO / US General Manager, PharmaEssentia
The Puerto Rico operation will support the company’s global manufacturing expansion strategy and is intended to serve as a future manufacturing center for the U.S. market and long-term global demand for BESREMi®, a treatment for adults with polycythemia vera (PV). The project reflects sustained global demand growth for the biologic, particularly in the U.S., as well as the potential additional demand growth from regulatory approvals for new uses.
Puerto Rico is widely recognized as a leading global hub for pharmaceutical manufacturing, hosting a strong ecosystem of experienced talent, infrastructure, and regulatory expertise. The planned manufacturing facility is expected to provide several long-term strategic benefits for PharmaEssentia, including enhanced supply security, increased operational flexibility, improved cost efficiency, and scalable manufacturing capacity to support future growth.
“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia as we continue to strengthen supply resilience, scalability, and geographic diversification,” said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer of PharmaEssentia. “We are proud to take this important step toward establishing U.S.-based manufacturing, with Puerto Rico serving as a future center for the U.S. market. This investment underscores our long-term commitment to reliably serving patients worldwide as demand for BESREMi® continues to grow.”
“PharmaEssentia’s decision to establish a manufacturing operation in Puerto Rico underscores the island’s role as a strategic U.S. hub for life sciences and advanced manufacturing,” said Governor of Puerto Rico Jennifer González. “This investment strengthens supply-chain resilience, creates high-value jobs, and reinforces Puerto Rico’s position as a trusted location for biopharmaceutical innovation and production serving patients in the United States and around the world.”
